MARKET

INSM

INSM

Insmed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

32.43
-0.07
-0.22%
Opening 15:45 05/07 EDT
OPEN
32.99
PREV CLOSE
32.50
HIGH
32.99
LOW
31.58
VOLUME
501.19K
TURNOVER
--
52 WEEK HIGH
45.44
52 WEEK LOW
22.65
MARKET CAP
3.35B
P/E (TTM)
-10.7935
1D
5D
1M
3M
1Y
5Y
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
, /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to nine new employees. In accordance ...
PR Newswire - PRF · 7h ago
H.C. Wainwright Reiterates a Buy Rating on Insmed (INSM)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Insmed (INSM) today and set a price target of $52.00. The company's shares closed last
SmarterAnalyst · 9h ago
8-K: INSMED Inc
falseINSMED INCORPORATED0001104506NASDAQ00011045062021-05-062021-05-06 --------------------------------------------------------------------------------...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 1d ago
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of 2.20% and 1.09%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1d ago
Insmed Q1 EPS $(0.89) Misses $(0.88) Estimate, Sales $40.21M Miss $41.64M Estimate
Insmed (NASDAQ:INSM) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.88) by 1.14 percent. This is a 20.27 percent decrease over losses of $(0.74) per share from the same
Benzinga · 1d ago
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 1d ago
BRIEF-Insmed Reports Q1 Loss Per Share Of $0.89
reuters.com · 1d ago
Insmed EPS misses by $0.01, misses on revenue
Insmed (INSM): Q1 GAAP EPS of -$0.89 misses by $0.01.Revenue of $40.21M (+9.1% Y/Y) misses by $1.35M.Press Release
Seekingalpha · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INSM. Analyze the recent business situations of Insmed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INSM stock price target is 53.56 with a high estimate of 60.00 and a low estimate of 41.00.
EPS
Institutional Holdings
Institutions: 306
Institutional Holdings: 121.68M
% Owned: 117.83%
Shares Outstanding: 103.27M
TypeInstitutionsShares
Increased
59
6.57M
New
33
3.92M
Decreased
81
9.27M
Sold Out
23
1.41M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.62%
Pharmaceuticals & Medical Research
+1.15%
Key Executives
Chairman/President/Chief Executive Officer/Director
William Lewis
Chief Financial Officer
Sara Bonstein
Chief Operating Officer
Roger Adsett
Chief Compliance Officer
John Soriano
Other
Martina Flammer
Other
Christine Pellizzari
Other
S. Nicole Schaeffer
Lead Director/Independent Director
David Brennan
Independent Director
Alfred Altomari
Independent Director
Elizabeth Anderson
Independent Director
Clarissa Desjardins
Independent Director
Steinar Engelsen
Independent Director
Leo Lee
Independent Director
David McGirr
Independent Director
Carol Schafer
Independent Director
Melvin Sharoky
No Data
About INSM
Insmed Incorporated is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Webull offers kinds of Insmed Incorporated stock information, including NASDAQ:INSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INSM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INSM stock methods without spending real money on the virtual paper trading platform.